Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 8.6% - Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price fell 8.6% on Monday . The stock traded as low as $22.09 and last traded at $21.63. 49,465 shares changed hands during trading, a decline of 80% from the average session volume of 242,814 shares. The stock had previously closed at $23.67.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DNTH. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating on the stock. Oppenheimer lifted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, November 11th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $46.83.

Dianthus Therapeutics Stock Up 4.7 %

The firm has a market cap of $638.41 million, a price-to-earnings ratio of -8.63 and a beta of 1.72. The business's fifty day moving average is $22.74 and its two-hundred day moving average is $25.36.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. Woodline Partners LP increased its position in shares of Dianthus Therapeutics by 20.0% in the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company's stock valued at $6,551,000 after buying an additional 50,000 shares in the last quarter. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 172.2% in the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after acquiring an additional 680,000 shares during the period. Octagon Capital Advisors LP raised its position in shares of Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after purchasing an additional 363,500 shares during the period. Millennium Management LLC lifted its holdings in shares of Dianthus Therapeutics by 160.2% during the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock valued at $1,972,000 after purchasing an additional 55,682 shares in the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of Dianthus Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock valued at $23,607,000 after purchasing an additional 136,314 shares during the period. Institutional investors own 47.53% of the company's stock.

Remove Ads

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.